26 reports

ACS Pipeline Competitors Fight Atherosclerosis via LDL and HDL Targets OF THE MANY POTENTIAL BIOLOGICAL AREAS TO TARGET IN ACS, THE CURRENT LATE-STAGE PIPELINE IS COMPOSED EXCLUSIVELY OF LIPID-MODIFYING DRUG CANDIDATES.

  • Lipid Modifying Drug
  • World
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • EVOLOCUMAB - DRUG PROFILE

The trials will evaluate alirocumab in combination with other lipid-lowering agents or as monotherapy across a broad patient population, including high cardiovascular risk patients with primary hypercholesterolemia, patients with primary hypercholesterolemia unable to tolerate stat

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Product Initiative
  • ANACETRAPIB - DRUG PROFILE

IT ACTS AS LIPID REGULATING AGENT.

  • Cholesterol
  • Chronic Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • Esperion Therapeutics, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Lipid-lowering Therapy, in Pediatric Subjects from ## to ## Years of Age with Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH) Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG ##) in Pediatric Subjects (##

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative

Niacin, Lipid Lowering Drug, was Less Used Due to Its Side Effects, Can Be Minimized by Adding Laropiprant.

  • Cardiovascular Disease
  • Clinical Trial
  • Endocrine Disease
  • Lipid Modifying Drug
  • AstraZeneca PLC
  • 5. All the trials included are unique trials.

Lipid Disorders Global Clinical Trials Review, H##, 2017 HEA LTH CA REHEA LTH CA RE REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: NOV 2017 LIST OF TABLES Lipid Disorders Global Clinical Trials Review, H##, 2017 outlines clinical trials in Lipid Disorders.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • 5. All the trials included are unique trials.

Lipid Lowering Therapy, in Subjects with Heterozygous or Homozygous Familial Hypercholesterolaemia An Open-label Study to Evaluate the Safety, Pharmacokinetics and Activity of PF-##, as Add-on to Stable Lipid Lowering Therapy, in Subjects with Heterozygous or Homozygous Famil

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Fruits on Lipid Profile in Dyslipidemia Patients Effects of Rhus Coriaria L.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World

AS A RESULT, PHYSICIANS MAY EXPECT POSITIVE CV OUTCOMES DATA BEFORE PRESCRIBING NEW LIPID-MODIFYING DRUG THERAPIES TO THE WIDER DYSLIPIDEMIA POPULATION.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • EVOLOCUMAB - DRUG PROFILE

Phase III - Trial Details EVOLOCUMAB - DRUG PROFILE Product Description Evolocumab (AMG-##, Repatha) is a monoclonal antibody acts as lipid modifying agent.

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.

The overall global pivotal Phase ## program is expected to enroll approximately ##, ## patients at high CVD risk with hypercholesterolemia on optimized background lipid-modifying therapy.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World

Niacin, Lipid Lowering Drug, was Less Used Due to Its Side Effects, Can Be Minimized by Adding Laropiprant.

  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • Product Initiative

Department of Veterans Affairs Joslin Diabetes Center ## Jan 2007 ## Aug 2010 ## ## ## ## A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-##) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-cl

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • Clinical Trial Profile Snapshots

Fruits on Lipid Profile in Dyslipidemia Patients Effects of Rhus Coriaria L.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Merck & Co., Inc.

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Inhibitor Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Phase I Clinical Trial of PF-## Phase I Clinical Trial of PF-## GDCT## GDC##, Cardiovascular Atherosclerosis, R

  • Cardiovascular Disease
  • Chronic Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • EVOLOCUMAB - DRUG PROFILE

Other Developmental Activities Product Description EVOLOCUMAB - DRUG PROFILE Evolocumab (AMG-##, Repatha) is a monoclonal antibody acts as lipid modifying agent.

  • Endocrine Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative
  • EVOLOCUMAB - DRUG PROFILE

TRIA-## IS AN ANTI-LIPIDEMIC AGENT CONTAINING ##-METHYLNICOTINAMIDE.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative
  • Clinical Trial Profile Snapshots

Fruits on Lipid Profile in Dyslipidemia Patients Effects of Rhus Coriaria L.

  • Cardiovascular Disease
  • Clinical Trial
  • Drug Discovery And Development
  • Lipid Modifying Drug
  • World

R& D Progress Research and Development Brief In 2011, MLT in licensed the lipid-altering agent Gemcabene (also known as CI-## and PD ##) from Pfizer.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • R&D
  • United States
  • Product Initiative
  • ANACETRAPIB - DRUG PROFILE

IT ACTS AS LIPID REGULATING AGENT.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • United States
  • Product Initiative

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

AS A RESULT, PHYSICIANS MAY EXPECT SIMILARLY STRINGENT STUDIES FOR NEW LIPID-MODIFYING DRUG THERAPIES.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

RECENT CLINICAL STUDIES OF THE EFFECTS OF LIPID-MODIFYING THERAPIES.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • AND APO B GENE SILENCERS

The trial recruited ##, ## patients from ## countries and investigated the lipid-modifying capacity of the drug in combination with statins with or without other lipid-modifying agents.

  • Lipid Modifying Drug
  • United States
  • Demand
  • Pfizer Inc.
  • Sanofi S.A.